Evidence-Based Hematology

1. Auflage 2008
ISBN: 978-1-4051-5747-6
Verlag: Turner Publishing Company

Buch, Englisch, 440 Seiten, Format (B × H): 230 mm x 284 mm, Gewicht: 1524 g

Reihe: Evidence-Based Medicine

This unique new book uses a series of focussed questions, comprehensive literature evaluations and structured grades of recommendation to provide evidence for the treatment of hematological disorders, both malignant and benign. With contributions from leading international experts who have a real understanding of evidence-based medicine the book provides comprehensive reviews accompanied by clinical commentaries and recommendations on the best treatment regimes to adopt for individual patients.

The book is split into two sections: the first examines the methodology underlying evidence based practice, and the second concentrates on the clinical practice of hematology, providing current "best evidence" to guide practice in a series of well-defined clinical situations.

This clinical reference is an invaluable source of evidence-based information distilled into guidance for clinical practice which will be welcomed by practitioners, trainees and associated health professionals.

Zielgruppe

Clinical hematologists and, oncologists, specialist trainees

Autoren/Hrsg.

Crowther, Mark A.

Ginsberg, Jeffrey

Schünemann, Holger

Meyer, Ralph M.

Lottenberg, Richard

Crowther, Mark A

Meyer, Ralph M

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Evidenzbasierte Medizin (EbM)
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hämatologie, Transfusionsmedizin

Inhaltsverzeichnis

About the Contributors.

Preface.

Part I: A Guide to the Evidence.

1. Rating the quality of evidence and making recommendations

2. An overview of systematic reviews

3. Interpreting results of clinical research

4. Finding the evidence

5. Applying EBM in clinical practice

6. Using evidence to guide the diagnosis of disease

Part II

7. Diagnosis of Deep Vein Thrombosis

8. Diagnosis of Pulmonary Embolism

9. Initial Therapy of Deep Vein Thrombosis and Pulmonary Embolism

10. Long-term Anticoagulation in Venous Thromboembolism

11. Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism

12. Inferior Vena Cava Interruption

13. Management of Venous Thromboembolism in Pregnancy

14. Pediatric Thrombosis

15. Bridging Anticoagulation in Patients who Require

16. Evidence-based approach to the diagnosis and management of thrombotic thrombocytopenic purpura

17. Diagnosis and Management of Disseminated Intravascular Coagulation

18. Diagnosis and Management of Hereditary Bleeding Disorders

19. Diagnosis and Management of Acquired Bleeding Disorders

20. Diagnosis and Management of Heparin-Induced Thrombocytopenia

21. Management of Antiphospholipid Antibody Syndrome

Part III

22. Clinical Questions in iron overload

23. Aplastic Anemia

24. Acquired Anemias

25. Immune thrombocytopenic purpura

26. Neutropenia

27. Hypereosinophilia

28. Porphyrias

29. Membrane and Enzyme Abnormalities of the Erythrocyte

30. Sickle cell disease

31. Evidence-based treatment of thalassemia major

Part IV

32. Acute Lymphoblastic Leukemia in Adults

33. Acute Myeloblastic Leukemia in Adults

34. Acute Myeloid Leukemia in Adults

35. Current Areas of Controversy in the Treatment of Patients

36. Chronic Lymphocytic Leukemia

37. Chronic Myelocytic Leukemia

38. Burkitt's Lymphoma

39. Primary Central Nervous System Lymphoma

40. Diffuse Large B-cell Lymphoma

41. Follicular Lymphoma

42. Lymphoblastic Lymphoma

43. Mantle Cell Lymphoma

44. Peripheral T-cell Lymphoma

45. Classical Hodgkin Lymphoma

46. Nodular Lymphocyte Predominant Hodgkin Lymphoma

47. Essential Thrombocythemia

48. Management of Patients with Polycythemia Vera

49. Multiple Myeloma

50. Waldenstroms Macroglobulinemia

51. Use of Hematopoietic Growth Factors for Hematologic Malignancies

Index.

Über Autor(innen)

Dr Mark Crowther is Associate Professor of Medicine and Program Director of the Adult Hematology Residency Training Program at McMaster University. He is a member of the Canadian Critical Care Trials Group.

Dr. Jeffrey Ginsberg is a leading expert in the diagnosis, prevention and management of venous thromboembolism and has led many of the "practice changing" studies published in this area in the last 20 years. He is the recipient of numerous awards and distinctions, most recently an endowed chair at McMaster University allowing him to pursue further research in venous and arterial thrombosis.

Dr. Holger Schünemann is a leading expert in evidence based practice with a particular interest in the development and widespread dissemination of validated evidence scoring criteria. Dr. Schünemann has played an important role in the evolution of evidence based guidelines currently written by organizations such as the American College of Chest Physicians and the American Thoracic Society.

Dr. Ralph Meyer has recently joined the National Cancer Institute of Canada after a distinguished career at McMaster University. Dr. Meyer is responsible for administering the Clinical Trial Program at the NCIC. The NCIC has led or participated in many national and international studies which guide current best treatment practices for disorders such as Hodgkin's disease, multiple myeloma and other hematologic malignancies.

Dr. Richard Lottenberg is a professor of medicine and past Division Chair of the division of Hematology and Oncology. He is currently the Training Program Director at the University of Florida and is widely regarded as an expert in the evidence based management of sickle cell anemia.